ACE2 News and Research

RSS

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).

22 May 2020

Preparing to meet SARS-CoV-2 head-on with a panel of neutralizing antibodies

A new study published on the preprint server bioRxiv in May 2020 describes a panel of neutralizing antibodies that bind to multiple attachment sites on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the current COVID-19 disease pandemic.

22 May 2020

RAAS inhibitors are safe to use in COVID-19 patients, study shows

The coronavirus disease (COVID-19) is a novel illness that has spread across the globe in just five months. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral infection binds to the angiotensin-converting enzyme 2 (ACE2) to enter and invade cells.

21 May 2020

Excessive blood clotting and stroke in COVID-19 patients

The coronavirus disease COVID-19 is causing excessive blood clotting and stroke in young and healthy people, a new study has found.

21 May 2020

Nasopharyngeal swab vs. saliva for COVID-19 diagnosis

One thing has become apparent in the ongoing pandemic of COVID-19. Early diagnosis and treatment, when necessary, is crucial to prevent the progression of the disease to critical and life-threatening stages where the mortality rate is much higher than otherwise. Rapid diagnosis is also key to containing outbreaks by allowing for efficient contact tracing in hospitals as well as in communities.

21 May 2020

Main receptors used by SARS-CoV-2 for cell entry are absent in the human placenta

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unlikely to infect human placenta through the canonical cell entry mediators, Wayne State University researchers showed that other interacting proteins may still play an important role during the viral infection. The study is currently available on the preprint server bioRxiv.

20 May 2020

Henry Ford Health System first to enroll a pediatric patient in HEROS study

Henry Ford Health System is first in the country to enroll a patient in the Human Epidemiology and Response to SARS-CoV-2 study, which aims to help determine the rate of SARS-CoV-2, the virus that causes COVID-19, among U.S. children and their family members, and what percentage of children infected with SARS-CoV-2 develop symptoms of the disease.

20 May 2020

Study shows engineered SARS-CoV-2 spike protein may be utilized for vaccine development

In a new study available on the preprint server bioRxiv, researchers demonstrate how the conformation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S-protein) can be controlled with the rational construct design, providing a framework for S-protein structure engineering in vaccine/drug development.

20 May 2020

Dana-Farber launches clinical test of blood cancer drug in COVID-19 patients

Scientists at Dana-Farber Cancer Institute have launched a clinical test of a blood cancer drug in patients infected with the COVID-19 virus. T

20 May 2020

Immunologists propose possible molecular mechanism for the deadly respiratory syndrome

Research into how the SARS-CoV-2 virus induces death is suggesting potential treatments for its most destructive complications.

20 May 2020

Does COVID-19 infect peripheral blood cells?

The emergence of the novel coronavirus outbreak in December 2019 was followed by its spread on a global scale unparalleled in the last 100 years. At present, it has claimed over 322,000 lives the world over, with over 4.88 million cases having tested positive.

19 May 2020

Sleep apnea may increase the risk of severe COVID-19, say researchers

An analysis conducted by researchers at the University of Turku and Turku University Hospital in Finland has suggested that obstructive sleep apnea (OSA) may be a risk factor for severe coronavirus disease 2019 (COVID-2019).

19 May 2020

New animal model for COVID-19

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to ravage the world, scientists are frantically searching for a vaccine or new drug that will effectively counter the lethal effects of the virus that leads to COVID-19 disease.

19 May 2020

Smoking increases ACE2 protein in the lungs which may promote COVID-19 infection

Previous data from COVID-19 patients suggests that cigarette smokers are more likely to have health complications.

18 May 2020

Potential new treatment approach to fatal COVID-19

Researchers from the University of Colorado Anschutz Medical Campus and Pathways Bioscience in the United States have found that activating a transcription factor involved in oxidative stress regulation, antiviral activity, and inflammation may serve as a new treatment approach to coronavirus disease 2019 (COVID-19).

18 May 2020

Novel insights on SARS-CoV-2 cell entry may inform further vaccine and treatment development

A research group from Harvard Medical School reported two cryo-electron microscopy structures derived from a single preparation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in their paper available on the preprint server bioRxiv. Understanding the nuances of prefusion and postfusion conformations shed light on viral cell entry and may, in turn, guide the development of vaccines and drugs.

18 May 2020

Cigarette smoke spurs the lungs to make more SARS-CoV-2 receptors

New research from CSHL scientists suggests that cigarette smoke spurs the lungs to make more ACE2 (angiotensin-converting enzyme 2), the protein that the coronavirus responsible for COVID-19 grabs and uses to enter human cells.

18 May 2020

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.

From Avacta Life Sciences Ltd. 18 May 2020

Research explores how human enzymes could be used to exacerbate COVID-19

Centenary Institute researchers have examined the critical role of human enzymes and the coronavirus in a newly published scientific review article that explores potential strategies for COVID-19 disease treatment and management.

18 May 2020

Host-virus interaction drives adaptive mutation in bat CoV related to SARS-CoVs

Virus and receptor diversity is shaped by the need to evolve advanced weaponry to facilitate virus entry and infection, on the one hand, and host resistance, on the other. A new paper published on the preprint server bioRxiv* shows how this mechanism operates in a bat coronavirus, which is related to the earlier SARS coronavirus.

17 May 2020